Advances in the therapeutic algorithm for myasthenia gravis

Nature Reviews Neurology, Published online: 30 May 2023; doi:10.1038/s41582-023-00825-yNew biologics are rapidly opening up target-specific therapeutic opportunities for myasthenia gravis (MG) — an autoimmune disease caused by antibodies against neuromuscular junction proteins. Two recent trials have now demonstrated the efficacy and tolerability of the complement C5 inhibitor zilucoplan and the FcRn inhibitor rozanolixizumab in patients with generalized MG.
Source: Nature Reviews Neurology - Category: Neurology Authors: Source Type: research